Crescent Biopharma, Inc. CBIO

Set alert

Price alert · CBIO

All alert types
12.91 USD -0.57 -4.23%

At close · Nov 2

12.91 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
12.89 × 2
Ask
12.91 × 2
12.68 Day range 13.92
8.72 52-week range 27.41
YTD
+8.85%
1 year
+1.25%
Open
13.75
Prev close
13.48
Mkt cap
479.57M
Vol
147.31K
Avg vol
345.98K
EPS
-7.63
P/E
0.00
Div yield
0.00%
More statistics
Low
12.68
High
13.92
Forward P/E
-17.04
Beta
1.29
Short ratio
0.19
Inst. own
8.75%
Dividend
15.94
Ex-div date
Jan 12, 2023
Earnings
Oct 26, 2023
50-d avg
0.638078
200-d avg
0.365086
1y target
0.00

30m chart

Chart tools
Interval

Chart is warming up

The thirty-minute interval price history for CBIO has not been loaded yet. Try again in a moment.

Analyst view

Consensus: hold

Hold
Price target (mean) 0.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 3
  • 1 month ago 1
  • 2 months ago 1
  • 3 months ago 3

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

CBIO analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.05-0.05 – -0.051.64-103.0%00.0%1
Next quarter-0.04-0.04 – -0.04-0.16+75.0%00.0%1
Current year0.000.00 – 0.000.000.0%00.0%0
Next year-0.03-0.03 – -0.030.000.0%00.0%1

Upgrades and downgrades

The latest rating changes

CBIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2021Raymond JamesDowngradeOutperformMarket Perform
Aug 5, 2021Raymond JamesMaintained—Outperform
Apr 28, 2021Raymond JamesMaintained—Outperform
Feb 9, 2021Piper SandlerInitiated—Overweight
Feb 3, 2021Raymond JamesMaintained—Outperform
Jan 3, 2019OppenheimerInitiated—Outperform
Jun 20, 2018B. Riley SecuritiesDowngradeBuyNeutral
Feb 11, 2018B. Riley SecuritiesMaintainedBuyBuy
Feb 8, 2018Chardan CapitalMaintainedBuyBuy
Dec 7, 2017B. Riley SecuritiesInitiated—Buy
Jun 11, 2017Chardan CapitalInitiated—Buy
Jun 5, 2017Ladenburg ThalmannInitiated—Buy
Jun 29, 2016Rodman & RenshawInitiated—Buy